Celularity Inc. is a U.S.-based biotechnology company focused on developing and commercializing cell-based and biomaterial products derived from the placenta and other biological sources. The company’s platform combines regenerative medicine, immunology, and advanced biomaterials, with an emphasis on therapies and products that can be used in wound care, tissue repair, and potential cell therapy applications. Celularity has also relied on capital markets financing and equity-linked transactions to fund operations and development activities. Its business model is still in an early commercialization and development phase, so execution depends heavily on clinical, regulatory, and financing milestones.
−203,4 %
24,4 %
−345,4 %
−51,0 %
0.15
0.15
| % | |
|---|---|
| Regenerative medicine and cell therapy | 40% Development of placenta-derived and other cell-based therapeutic programs intended for tissue repair and immune-related applications. |
| Biomaterials and wound care | 35% Biologic materials and tissue-derived products used in wound healing and related clinical applications. |
| Research and development platform | 15% Preclinical, translational, and platform development work supporting future product candidates and partnerships. |
| Strategic and financing-related activities | 10% Equity-linked and advisory arrangements that support liquidity and corporate development. |
Celularity’s customers are primarily healthcare providers, clinicians, and institutions that use biologic wound care or...
Hospitals, wound care centers, and clinics buy biologic products for patient treatment because they need clinically usable regenerative or wound-healing solutions.
Biotech, academic, and clinical partners engage with the platform to advance development programs and validate therapeutic applications.
Investors and financing counterparties provide funding through equity-linked instruments and private placements to support operations and development.
Patients and treating physicians are the eventual end market for approved cell therapy or regenerative medicine products.
Celularity is headquartered in the United States and its reported financing and corporate activity are centered there...
Celularity’s strategy appears centered on advancing its biologic platform while preserving liquidity through capital...
The company needs external capital to fund ongoing development and corporate operations before product scale is achieved.
Clinical and commercial progress is necessary to convert the platform into durable revenue and strategic value.
Partnerships and advisory support can improve access to markets, capital, and commercialization pathways.
Celularity faces the typical risks of an early-stage biotechnology company, including clinical failure, regulatory...
The company has relied on private placements, convertible notes, and equity issuances to fund operations, indicating ongoing dependence on capital markets.
Convertible notes and preferred stock can convert into common shares, increasing share count and reducing existing shareholders' ownership percentage.
Therapeutic and biologic programs require successful development, regulatory clearance, and evidence of safety and efficacy before meaningful commercialization.
Even approved biologic products can face slow uptake if clinicians or payers do not support use or reimbursement is limited.
CERO · Biological Products, (No Diagnostic Substances)
CELC · Services-Medical Laboratories
BRTX · Services-Misc Health & Allied Services, NEC
ISCO · Pharmaceutical Preparations
SMTI · Orthopedic, Prosthetic & Surgical Appliances & Supplies
BCTX · Pharmaceutical Preparations
: 28/04/2026